Recent developments in the psychopharmacology of anxiety disorders.

Lydiard, R. Bruce, Brawman-Mintzer, Olga, Ballenger, James C.·1996·Journal of Consulting and Clinical Psychology

Abstract

Anxiety disorders are the most prevalent mental disorders in the United States. In the past 3 decades, substantial advances have been made in the ability to identify and treat anxiety disorders including panic disorder (PD), social phobia (SP), obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD), and posttraumatic stress disorder (PTSD). It is now known that these common, usually chronic disorders confer significant disability to untreated sufferers. This overview highlights some of the important advances in pharmacological treatment of anxiety disorders. Evidence for efficacy of the various pharmacological agents (including relevant oral dosing and plasma-level data) and of acute and long-term treatment, and the disadvantages of medication treatment are discussed. Finally, some important clinical questions remaining to be addressed by psychopharmacological research are reviewed.

Cites (9)

  1. Untitled work
    Schneier · 1992 · 10.1001/archpsyc.1992.01820040034004
  2. Alprazolam in Panic Disorder and Agoraphobia: Results From a Multicenter Trial: I. Efficacy in Short-term Treatment
    Ballenger, James C. · 1988 · Archives of General Psychiatry
  3. Phenelzine vs Atenolol in Social Phobia: A Placebo-Controlled Comparison
    Liebowitz, Michael R., Schneier, Frank, Campeas, Raphael, Hollander, Eric, Hatterer, Julie, Fyer, Abby, Gorman, Jack, Papp, Laslo, Davies, Sharon, Gully, Robert et al. · 1992 · Archives of General Psychiatry
  4. Cognitive-Behavioral and Pharmacological Treatments of Social Phobia: A Controlled Study
    Gelernter, Cheryl Shea · 1991 · Archives of General Psychiatry
  5. Long-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
    Rickels, Karl · 1990 · Archives of General Psychiatry
  6. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder
    1988 · American Journal of Psychiatry
  7. Discontinuation of benzodiazepine treatment: efficacy of cognitive- behavioral therapy for patients with panic disorder
    1993 · American Journal of Psychiatry
  8. Paroxetine in the Treatment of Panic Disorder a Randomised, Double-Blind, Placebo-Controlled Study
    Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., Calberg, H., Judge, R., Ohrstrom, J. K., Manniche, P. M. · 1995 · British Journal of Psychiatry
  9. Does Cognitive Behavior Therapy Assist Slow-Taper Alprazolam Discontinuation in Panic Disorder?
    1994 · American Journal of Psychiatry

Show all 9 references

Cited by (12)

  1. Cognitive-Behavioral Therapy, Imipramine, or Their Combination for Panic Disorder: A Randomized Controlled Trial
    Barlow, David H., Gorman, Jack M., Shear, M. Katherine, Woods, Scott W. · 2000 · JAMA
  2. Enduring Effects for Cognitive Behavior Therapy in the Treatment of Depression and Anxiety
    Hollon, Steven D., Stewart, Michael O., Strunk, Daniel · 2006 · Annual Review of Psychology
  3. Dropping out of mental health treatment: patterns and predictors among epidemiological survey respondents in the United States and Ontario
    Edlund, Mark J., Wang, Philip S., Berglund, Patricia A., Katz, Stephen J., Lin, Elizabeth, Kessler, Ronald C. · 2002 · American Journal of Psychiatry
  4. Paroxetine Treatment of Generalized Social Phobia (Social Anxiety Disorder): A Randomized Controlled Trial
    Stein, Murray B., Liebowitz, Michael R., Lydiard, R. Bruce, Pitts, Cornelius D., Bushnell, William, Gergel, Ivan · 1998 · JAMA
  5. Mood, personality disorder symptoms and disability in obsessive compulsive hoarders: a comparison with clinical and nonclinical controls
    Frost, Randy O., Steketee, Gail, Williams, Lauren F., Warren, Ricks · 2000 · Behaviour Research and Therapy

See all 91

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recent developments in the psychopharmacology of anxiety disorders. https://app.cochat.ai/papers/10.1037//0022-006x.64.4.660
The paper
Lydiard, R. B., Brawman-Mintzer, O., & Ballenger, J. C. (1996). Recent developments in the psychopharmacology of anxiety disorders. Journal of Consulting and Clinical Psychology. https://doi.org/10.1037//0022-006x.64.4.660

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.